en POLSKI
eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2021
vol. 27
 
Share:
Share:
abstract:
Case report

Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports

Iwona Pietrzak
1
,
Agnieszka Szadkowska
1

  1. Department of Pediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, Poland
Pediatr Endocrinol Diabetes Metab 2021; 27 (4): 305–310
Online publish date: 2021/12/30
View full text Get citation
 
PlumX metrics:
The aim of modern insulin therapy used in the treatment of type 1 diabetes mellitus is to mimic the physiological secretion of insulin in order to ensure stable normoglycemia while maintaining the greatest possible comfort of life for diabetic patients. New ultra-fast insulin analogs that can be administered immediately before a meal contribute to the improvement of postprandial glycemia and the quality of life of patients. We presented two cases illustrating the effectiveness and safety of the use of an ultra-fast-acting insulin analog in the treatment of postprandial hyperglycemia in children with type 1 diabetes.
keywords:

type 1 diabetes mellitus, postprandial hyperglycemia, time in range, ultrafast-acting analog of insulin, children


Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.